Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Preliminary experience using high-intensity focused ultrasound for the treatment of kidney and liver tumours

Illing RO. et al, (2004), BRITISH JOURNAL OF CANCER, 91, S21 - S21

Contrast-enhanced ultrasound assessment of tissue response to high-intensity focused ultrasound.

Kennedy JE. et al, (2004), Ultrasound Med Biol, 30, 851 - 854

DNA repair pathways in drug resistance in melanoma.

Bradbury PA. and Middleton MR., (2004), Anticancer Drugs, 15, 421 - 426

DNA repair pathways in drug resistance in melanoma

Bradbury PA. and Middleton MR., (2004), ANTI-CANCER DRUGS, 15, 421 - 426

High-intensity focused ultrasound for the treatment of liver tumours.

Kennedy JE. et al, (2004), Ultrasonics, 42, 931 - 935

Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.

Hancock BW. et al, (2004), J Clin Oncol, 22, 53 - 61

Adult idiopathic thrombocytopenic purpura.

Mead AJ. et al, (2003), Hematology, 8, 345 - 357

Performance status score: do patients and their oncologists agree?

Blagden SP. et al, (2003), Br J Cancer, 89, 1022 - 1027

Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma.

Danson S. et al, (2003), Cancer, 98, 542 - 553

Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.

Danson S. et al, (2003), J Clin Oncol, 21, 2551 - 2557

Polar expeditions--provisioning the centrosome for mitosis.

Blagden SP. and Glover DM., (2003), Nat Cell Biol, 5, 505 - 511

BDS Melanoma Guidelines.

Middleton M. et al, (2003), Br J Dermatol, 148, 1081 - 1082

Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine.

Kiebert GM. et al, (2003), Cancer Invest, 21, 821 - 829

Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway.

Middleton MR. and Margison GP., (2003), Lancet Oncol, 4, 37 - 44

Brain metastases in melanoma: a European perspective.

Cattell E. et al, (2002), Semin Oncol, 29, 513 - 517

Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patients.

Corrie P. et al, (2002), Br J Cancer, 87, 716 - 719

Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model.

Middleton MR. et al, (2002), Int J Cancer, 100, 615 - 617

Pharmacokinetics of histamine dihydrochloride in healthy volunteers and cancer patients: implications for combined immunotherapy with interleukin-2.

Middleton M. et al, (2002), J Clin Pharmacol, 42, 774 - 781

Assessing outcomes in palliative chemotherapy.

Cattell E. et al, (2002), Expert Opin Pharmacother, 3, 693 - 700

Toxicity of temozolomide with response modifiers in metastatic malignant melanoma

Lorigan P. et al, (2002), BRITISH JOURNAL OF CANCER, 86, S68 - S68

«
...
62
63
64
65
66
67